SCHEMBL2659536

SCHEMBL2659536

O=C(O)CCNC(=O)c1ccc(C(CC(=O)c2cccc(SC(F)(F)F)c2)C(=O)c2cccc(Br)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
GCGR P47871 10/20 0.40
L3MBTL1 Q9Y468 1/20 0.38
KCNK2 O95069 2/20 0.38
KCNK10 P57789 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
GCG P01275 1/20 0.37
TP53BP1 Q12888 1/20 0.36
ADCY6 O43306 3/20 0.36
ADCY3 O60266 3/20 0.36
ADCY9 O60503 3/20 0.36
ADCY5 O95622 3/20 0.36
ADCY8 P40145 3/20 0.36
ADCY7 P51828 3/20 0.36
ADCY2 Q08462 3/20 0.36
ADCY1 Q08828 3/20 0.36
ADCY4 Q8NFM4 3/20 0.36
NFKB1 P19838 1/20 0.36
CASP3 P42574 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2654298 0.94 LMNA (0.44) LMNAGCGRL3MBTL1KCNK2KCNK10
SCHEMBL2659923 0.89 GCGR (0.45) GCGRKCNK2GCGADCY6ADCY3
SCHEMBL2660139 0.88 GCGR (0.40) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2654573 0.88 GCGR (0.49) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2654228 0.88 GCGR (0.40) GCGRGCGADCY6ADCY3ADCY9
SCHEMBL2653443 0.87 GCGR (0.44) GCGRKCNK2KCNK10ADCY6ADCY3
SCHEMBL2659948 0.86 GCGR (0.49) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2660316 0.86 GCGR (0.45) GCGRGCGADCY6ADCY3ADCY9
SCHEMBL2665073 0.84 GCGR (0.43) GCGRGCGGLP1R
SCHEMBL2660535 0.84 GCGR (0.43) GCGRGCGGLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152750-A1 Novel glucagon antagonists NOVO NORDISK A/S (DK) 2004-08-05 US disclosed
WO-2004056763-A2 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2004-07-08 WO disclosed
WO-2004056763-A2 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152750-A1 Novel glucagon antagonists GLP1R, GCGR, GIPR LMNA 4032/4885GCGR 2/4885L3MBTL1 1660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.